FY2025 EPS Estimates for IVERIC bio, Inc. (NASDAQ:ISEE) Reduced by Jefferies Financial Group

IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) – Research analysts at Jefferies Financial Group dropped their FY2025 earnings per share (EPS) estimates for IVERIC bio in a research report issued on Wednesday, May 4th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will earn $1.09 per share for the year, down from their previous forecast of $1.12. Jefferies Financial Group currently has a “Buy” rating and a $27.00 target price on the stock. Jefferies Financial Group also issued estimates for IVERIC bio’s FY2026 earnings at $3.77 EPS.

Several other brokerages also recently weighed in on ISEE. StockNews.com began coverage on shares of IVERIC bio in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Robert W. Baird began coverage on shares of IVERIC bio in a report on Thursday, March 3rd. They set an “outperform” rating and a $27.00 price objective on the stock. Morgan Stanley began coverage on shares of IVERIC bio in a report on Monday, February 7th. They set an “overweight” rating and a $25.00 price objective on the stock. Stifel Nicolaus boosted their price objective on shares of IVERIC bio from $22.00 to $28.00 in a report on Wednesday. Finally, Zacks Investment Research raised shares of IVERIC bio from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Wednesday, April 27th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, IVERIC bio presently has a consensus rating of “Buy” and a consensus price target of $23.71.

NASDAQ ISEE traded down $0.41 during trading on Friday, reaching $12.68. The company’s stock had a trading volume of 12,165 shares, compared to its average volume of 1,285,033. The business’s fifty day moving average price is $15.89 and its 200-day moving average price is $15.56. IVERIC bio has a twelve month low of $5.72 and a twelve month high of $19.34.

IVERIC bio (NASDAQ:ISEEGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.29) EPS for the quarter, meeting analysts’ consensus estimates of ($0.29). During the same quarter last year, the business earned ($0.29) earnings per share.

In other IVERIC bio news, COO Keith Westby sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 7th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Glenn Sblendorio sold 3,479 shares of the firm’s stock in a transaction on Friday, March 18th. The shares were sold at an average price of $17.00, for a total transaction of $59,143.00. The disclosure for this sale can be found here. Insiders have sold 178,682 shares of company stock valued at $3,151,931 in the last ninety days. 2.70% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the business. Deep Track Capital LP purchased a new position in shares of IVERIC bio in the fourth quarter worth approximately $66,880,000. Perceptive Advisors LLC grew its position in IVERIC bio by 62.9% during the third quarter. Perceptive Advisors LLC now owns 7,471,798 shares of the company’s stock valued at $121,342,000 after purchasing an additional 2,886,286 shares in the last quarter. Invesco Ltd. grew its position in IVERIC bio by 6,276.6% during the third quarter. Invesco Ltd. now owns 2,115,502 shares of the company’s stock valued at $34,355,000 after purchasing an additional 2,082,326 shares in the last quarter. TCG Crossover Management LLC acquired a new stake in IVERIC bio in the fourth quarter valued at approximately $29,113,000. Finally, Polar Capital Holdings Plc acquired a new stake in IVERIC bio in the third quarter valued at approximately $25,098,000.

About IVERIC bio (Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

See Also

Earnings History and Estimates for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.